Sheena Bhalla

2.3k total citations · 1 hit paper
26 papers, 1.3k citations indexed

About

Sheena Bhalla is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Sheena Bhalla has authored 26 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Hematology. Recurrent topics in Sheena Bhalla's work include Lung Cancer Treatments and Mutations (6 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Global Cancer Incidence and Screening (4 papers). Sheena Bhalla is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Global Cancer Incidence and Screening (4 papers). Sheena Bhalla collaborates with scholars based in United States, France and India. Sheena Bhalla's co-authors include Deborah B. Doroshow, Fred R. Hirsch, Ignacio I. Wistuba, Mary Beth Beasley, Keith M. Kerr, Sacha Gnjatic, Lynette M. Sholl, David L. Rimm, Ming‐Sound Tsao and David E. Gerber and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Sheena Bhalla

24 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

2021 980 citations Deborah B. Doroshow, Sheena Bhalla et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sheena Bhalla United States	8	775	372	327	301	144	26	1.3k
Ulf Petrausch Switzerland	23	1.1k 1.4×	450 1.2×	289 0.9×	289 1.0×	129 0.9×	62	1.6k
Alex Chehrazi‐Raffle United States	11	869 1.1×	461 1.2×	331 1.0×	374 1.2×	171 1.2×	64	1.3k
Anne Cairoli Switzerland	8	1.3k 1.6×	478 1.3×	366 1.1×	242 0.8×	67 0.5×	26	1.7k
Keyvan Shabafrouz Switzerland	3	1.2k 1.6×	471 1.3×	345 1.1×	229 0.8×	67 0.5×	6	1.6k
Stefan Kasper Germany	24	885 1.1×	448 1.2×	397 1.2×	636 2.1×	190 1.3×	122	2.0k
Alessandra Curioni‐Fontecedro Switzerland	24	909 1.2×	424 1.1×	722 2.2×	398 1.3×	173 1.2×	87	1.8k
Ernesto Rossi Italy	19	446 0.6×	255 0.7×	206 0.6×	250 0.8×	87 0.6×	72	894
Julian A. Marin‐Acevedo United States	13	1.1k 1.5×	732 2.0×	358 1.1×	354 1.2×	151 1.0×	27	1.7k
Fabio Conforti Italy	18	1.2k 1.5×	390 1.0×	522 1.6×	398 1.3×	197 1.4×	78	1.9k
Alejandra Flores-Chávez Spain	9	730 0.9×	403 1.1×	230 0.7×	157 0.5×	43 0.3×	18	1.2k

Countries citing papers authored by Sheena Bhalla

Since Specialization

Citations

This map shows the geographic impact of Sheena Bhalla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheena Bhalla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheena Bhalla more than expected).

Fields of papers citing papers by Sheena Bhalla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheena Bhalla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheena Bhalla. The network helps show where Sheena Bhalla may publish in the future.

Co-authorship network of co-authors of Sheena Bhalla

This figure shows the co-authorship network connecting the top 25 collaborators of Sheena Bhalla. A scholar is included among the top collaborators of Sheena Bhalla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheena Bhalla. Sheena Bhalla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bhalla, Sheena, Song Zhang, Jessica L. Lee, et al.. (2025). Mortality in a Diverse, Real-World Lung Cancer Screening Cohort. Clinical Lung Cancer. 26(6). e441–e446. 1 indexed citations

Bhalla, Sheena, Jessica L. Lee, Hong Zhu, et al.. (2024). Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable Populations. Journal of the National Comprehensive Cancer Network. 22(3). 151–157. 5 indexed citations

Gerber, David E., Yating Wang, Suresh S. Ramalingam, et al.. (2024). Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer. The Oncologist. 29(4). 342–349.

Zhang, Yuanyuan, Puneeth Iyengar, Kenneth D. Westover, et al.. (2024). Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brief Report. International Journal of Radiation Oncology*Biology*Physics. 121(1). 68–74. 1 indexed citations

Bhalla, Sheena, Jessica L. Lee, Travis Browning, et al.. (2024). Geographic Accessibility and Completion of Initial Low-Dose CT-Based Lung Cancer Screening in an Urban Safety-Net Population. Journal of the National Comprehensive Cancer Network. 22(5). 308–314. 3 indexed citations

Lee, Simon J. Craddock, Jessica L. Lee, Hong Zhu, et al.. (2023). Assessing Barriers and Facilitators to Lung Cancer Screening: Initial Findings from a Patient Navigation Intervention. Population Health Management. 26(3). 177–184. 6 indexed citations

Bhalla, Sheena, Farjana Fattah, Chul Ahn, et al.. (2023). Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer. Lung Cancer. 182. 107291–107291. 23 indexed citations

Bhalla, Sheena & David E. Gerber. (2023). AXL Inhibitors: Status of Clinical Development. Current Oncology Reports. 25(5). 521–529. 28 indexed citations

Veluswamy, Rajwanth, Sheena Bhalla, Robert Samstein, et al.. (2022). 1018P Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients. Annals of Oncology. 33. S1019–S1020. 2 indexed citations

10.

Doroshow, Deborah B., Sheena Bhalla, Mary Beth Beasley, et al.. (2021). PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology. 18(6). 345–362. 980 indexed citations breakdown →

11.

Doroshow, Deborah B., Andrew Schmidt, Ziad Bakouny, et al.. (2020). LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS). Annals of Oncology. 31. S1204–S1204. 4 indexed citations

12.

Naymagon, Leonard, Nicole Zubizarreta, Jonathan Feld, et al.. (2020). Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19. Thrombosis Research. 196. 99–105. 83 indexed citations

13.

Bhalla, Sheena, Deborah B. Doroshow, & Fred R. Hirsch. (2020). Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non–Small Cell Lung Cancer. The Cancer Journal. 26(6). 507–516. 4 indexed citations

14.

Tremblay, Douglas, Carina Seah, Thomas Schneider, et al.. (2020). Convalescent Plasma for the Treatment of Severe COVID‐19 Infection in Cancer Patients. Cancer Medicine. 9(22). 8571–8578. 32 indexed citations

15.

Kamath, Geetanjali R., Douglas Tremblay, Alexander Coltoff, et al.. (2019). Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia. Carcinogenesis. 40(5). 651–660. 12 indexed citations

16.

Tremblay, Douglas, et al.. (2018). Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies.. PubMed. 32(5). e45–e51. 6 indexed citations

17.

Tremblay, Douglas, et al.. (2018). Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia.. PubMed. 32(4). e38–e44. 6 indexed citations

18.

Bhalla, Sheena, Douglas Tremblay, & John Mascarenhas. (2016). Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions. Clinical Lymphoma Myeloma & Leukemia. 16(9). 488–494. 8 indexed citations

19.

Bhalla, Sheena, et al.. (2013). Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid. British Journal of Ophthalmology. 97(7). 895–899. 29 indexed citations

20.

Bhalla, Sheena, et al.. (1981). A focus of chloroquine resistance in Plasmodium falciparum in Shaktinagar area of Mirzapur District, Uttar Pradesh. 18(1). 35–40. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact